ストックスクリーナーアプリを入手
57.16
0.82%
-0.47
アフターアワーズ：
57.16
前日終値:
$57.63
開ける：
$57.635
24時間の取引高:
2.23M
Relative Volume:
0.77
時価総額：
$25.45B
収益：
$2.44B
当期純損益:
$1.36B
株価収益率:
29.94
EPS:
1.9093
ネットキャッシュフロー:
$574.14M
1週間 パフォーマンス:
-1.80%
1か月 パフォーマンス:
-9.43%
6か月 パフォーマンス:
+17.69%
1年 パフォーマンス:
+56.65%
1日の値動き範囲:
$56.96
$57.91
1週間の範囲:
$56.96
$58.77
52週間の値動き範囲:
$35.23
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
57.16 | 25.92B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - theglobeandmail.com
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Form 4 Royalty Pharma Plc For: 1 October - Investing.com India
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock - MarketBeat
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD - TradingView
RPD Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria
RPHC5824522 Bond Profile: Coupon and Redemption - TradingView
Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan
Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Australia
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Eastern Progress
Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada
Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Singapore
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts - MarketBeat
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? - The Motley Fool
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,853,000.00 in Stock - MarketBeat
A prearranged plan governed SCH Investment Partners’ sale of 100,000 Royalty Pharma (RPRX) shares. - Stock Titan
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
RPHC5237354 Bond Profile: Coupon and Redemption - TradingView
Royalty Pharma PLC (RPD) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
RPRX: Strategic AI, scalable deal models, and China expansion drive robust, diversified growth - TradingView
Royalty Pharma PLC (RPD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks - Investing.com Nigeria
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns - Yahoo Finance
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPD) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.62%
4.96%
大文字化:
|
ボリューム (24 時間):